Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People being treated with Koselugo (Selumetinib) in South Korea, where this treatment has been officially approved for use.
- A signed and dated consent form must be provided by the patient or their legal representative before joining.
Who may not be able to join:
- The exclusion criteria listed in the source appear to be identical to the inclusion criteria, which may be an error in the original document (confirm with trial site).
- Similarly, the consent requirement is repeated as an exclusion criterion, which may also be a documentation error (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse events (AEs) rate; Physeal dysplasia occurance rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.